These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic gene modified cell based cancer vaccines. Kozłowska A; Mackiewicz J; Mackiewicz A Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846 [TBL] [Abstract][Full Text] [Related]
5. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Baxevanis CN; Papamichail M Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086 [TBL] [Abstract][Full Text] [Related]
6. Regulation of the MIR155 host gene in physiological and pathological processes. Elton TS; Selemon H; Elton SM; Parinandi NL Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031 [TBL] [Abstract][Full Text] [Related]
10. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach. Sinkovics JG Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421 [TBL] [Abstract][Full Text] [Related]
11. Biological drug and drug delivery-mediated immunotherapy. Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408 [TBL] [Abstract][Full Text] [Related]
13. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322 [TBL] [Abstract][Full Text] [Related]
14. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137 [No Abstract] [Full Text] [Related]
15. The T-body approach: redirecting T cells with antibody specificity. Eshhar Z Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952 [TBL] [Abstract][Full Text] [Related]
16. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Chmielewski M; Hombach AA; Abken H Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791 [TBL] [Abstract][Full Text] [Related]